IBD Therapeutics Incubator
Funds long-term academic-industry collaborations to advance new inflammatory bowel disease treatment targets.
The IBD Therapeutics Incubator is the Crohn's & Colitis Foundation's collaborative drug-discovery route for Crohn's disease and ulcerative colitis. It pairs academic researchers with a specialized CRO and the Foundation's drug discovery staff to advance novel or validated drug targets into therapeutic products. Awards can reach $1.5 million over three years, and most of the budget is directed to CRO work rather than the investigator's lab. The call is rolling or announced by RFP, with no fixed annual deadline, and applicants need targets that are novel, biologically grounded, druggable, and supported by preclinical proof of concept. The program is designed for teams that can satisfy a long scientific screen: relevant disease biology, assay availability, tool compounds or antibodies, biomarkers, and a favorable safety profile. It is not a passive grant and works best when the academic partner is ready to operate inside a Foundation-led translational project, with the external CRO carrying much of the execution. The funding is set up to move a defined target, not to support basic science in isolation.
No upcoming rounds verified. Cadence: Rolling.